Trials / Completed
CompletedNCT05779007
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,778 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone | Pirfenidone |
| DRUG | Nintedanib | Nintedanib |
Timeline
- Start date
- 2023-04-18
- Primary completion
- 2023-07-14
- Completion
- 2023-07-14
- First posted
- 2023-03-22
- Last updated
- 2025-07-28
- Results posted
- 2025-07-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05779007. Inclusion in this directory is not an endorsement.